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Abstract 
Objective 
Misuse of codeine containing medicines in combination with new psychoactive 
substances (NPS) is inadequately described. This study characterises codeine 
consumption amongst NPS users and non-NPS users to provide warning of health 
issues. 
Methods 
Online survey conducted between July 2015 and March 2016. 
Results 
Out of 340 respondents, residing in a country in Europe and using codeine recently, 
63.8% were female. Mean age: 34.9 years (SD = 12.4). Substance use included 
NPS (18.5%) and illicit controlled drugs (55.9%). Factors relating to codeine use 
found to significantly predict NPS use were consuming codeine extracted from 
combination tablets (OR = 16.79, 95% CI = 8.67−32.51), obtaining codeine from 
friends, family and acquaintances (OR = 3.98, 95% CI = 1.82−8.7), use of illicit 
controlled drugs (OR = 34.99, 95% CI = 8.39−145.94) and use of codeine to 
experience euphoria (OR = 6.41, 95% CI 3.42−12.04). 
Conclusions 
Amongst NPS users, codeine is less likely to be used daily, but more likely to be 
used for recreational purposes. Smaller populations engaging in high-risk use exist 
who take multiple drugs in high doses. Combinations of misused codeine and NPS 
highlight the need for policy to respond to a more complex drug situation. 
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Introduction 
In the annual review of the European drug situation, the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) 2016 Drug Report stated: ‘Europe 
increasingly faces a more complex drug problem, in which stimulants, new 
psychoactive substances, misused medicines and problematic cannabis use all play 
a greater part’ (EMCDDA, 2016a). Separately, these substance classes create their 
own set of problems for public health: Diverted and misused prescription opioids 
causing fatal poisonings add complexity to the opioid problem in Europe (Office for 
National Statistics, 2016; Weisberg, Becker, Fiellin, & Stannard, 2014; Stannard, 
2013); whilst a massive growth in the availability of new psychoactive substances 
(NPS) poses new challenges to regulators. At the same time, complex patterns are 
emerging where misused medicines, NPS and illicit controlled drugs are used 
together or in replacement of one another. Currently, gaps exist in our understanding 
of concurrent use of medicines and NPS and health risks posed. 
Use and misuse of opioid analgesics 
Use of opioid analgesics more than doubled in central Europe from around half a 
billion defined daily doses (DDD) per year in 2001-03 to about 1.6bn DDD per year in 
2011-13 (Berterame et al., 2016). This has been accompanied by misuse, diversion, 
dependence and non-fatal and fatal overdoses (Weisberg et al., 2014; Office for 
National Statistics, 2016). This development has been registered in treatment 
services across Europe that are increasingly having to react to patients entering for 
misused medicines (EMCDDA, 2015a; Parry, Deluca, Cooper, & Van Hout, 2015). 
Whilst heroin remains a principal drug in drug-related deaths in Europe, other opioids 
have become more prominent in national data (EMCDDA, 2016b; Office for National 
Statistics, 2016). Tampering of medicines to enhance drug effects (Kimergård, 
Breindahl, Hindersson, & Deluca, 2016a) and transitions from weak to more toxic 
opioids and to heroin highlight unique concerns with misused medicines (Conroy & 
Hill, 2015). 
NPS in Europe 
Information from the EU Early Warning System show just how extensive the market 
for NPS has become. In the past five years alone, hundreds of new substances have 
appeared on the market (EMCDDA, 2015b; 2016a; 2016b). Sold as ‘legal highs’, 
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‘bath salts’, and ‘research chemicals’ on the Internet, and from marketplaces on the 
hidden web (Dolliver & Kuhns, 2016), global transportation networks offer prompt 
delivery of NPS worldwide. The emergence of some new substances has a strong 
link with their misuse as medicines (Brandt, King, & Evans-Brown, 2014). Fentanyl 
provides a good, albeit troubling example: Prescribed for severe pain caused by 
cancer and other debilitating and serious diseases, reports have highlighted the 
potential for fentanyl misuse associated with clusters of deaths (Mounteney, 
Giraudon, Denissov, & Griffiths, 2015). At the same time, fentanyl analogues have 
been identified on the illicit market since the late 1970s where α-methylfentanyl was 
first passed off as heroin substitutes in the US (Henderson, 1988; Kram, Cooper, & 
Allen, 1981). Since 2014, acetylfentanyl has been involved in hundreds of deaths in 
Europe, the US, Russia and elsewhere (DEA Office of Diversion Control, 2015; 
EMCDDA, 2016b; Melent’ev, Kataev, & Dvorskaya, 2015). Two years later, 
acrylfentanyl entered the market (Breindahl, Kimergård, Andreasen, & Pedersen, 
2017) and has already been implicated in over 40 deaths (EMCDDA, 2017). 
The complexity of polysubstance use 
Reports now highlight complex relationships between misused medicines and the 
use of NPS in place of and in addition to heroin and other illicit controlled drugs 
(EMCDDA, 2016a). An Australian study examining use of ‘over-the-counter’ codeine 
found an overlap between codeine use and recent use of heroin, methadone, and 
morphine amongst injecting drug users (Arora, Roxburgh, Bruno, Nielsen, & Burns, 
2013). In a cross-European survey, 43% indicated non-medical prescription opioid 
use and use of illicit controlled drugs in the past year in the UK, 41% did so in 
Sweden, 30% in Germany, 24% in Denmark and 21% in Spain (Novak et al., 2016). 
Cannabis was the most frequently used illicit controlled drug in the survey. The 
Crime Survey for England and Wales found that 0.7% adults had used NPS in the 
past year (2015/16) (Lader, 2016). The survey estimated that 7.5% adults had taken 
a prescription opioid not prescribed to them, with 0.2% indicating that they took it for 
the ‘feeling or experience’ it gave them. Elliot & Evans (2014) performed a three-year 
review of NPS in post-mortem and criminal casework and found that 84% of cases 
with presence of NPS also contained other drugs, medicines or alcohol, underlining 
that polysubstance use affects levels of harm. 
Misused codeine containing medicines 
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Codeine is currently one of the most used opioids globally (International Narcotics 
Control Board, 2015) and widely misused and associated with dependence in many 
countries in Europe (Cooper, 2013; Kimergård et al., 2017; Van Hout, Horan, Santlal, 
Rich, & Bergin, 2015; Roussin, Bouyssi, Pouché, Pourcel, & Lapeyre-Mestre, 2013). 
Regulations by medicine authorities to ensure legitimate supply and use of codeine 
containing medicines are in place at the international and national level across 
Europe. In many countries, codeine is supplied with a medical prescription. However, 
in several European countries, codeine formulations containing lower amounts of 
codeine can also be purchased ‘over-the-counter’ in licensed pharmacies (Foley et 
al., 2015). Studies have described misuse and dependence on codeine following use 
for appropriate medical reasons (Cooper, 2013; Kimergård et al., 2017). However, 
little is known about the role codeine plays in experimental use with additional 
research needed to investigate overlaps between misused codeine and the use of 
NPS. This present study focussed on people indicating recent use of codeine 
containing medicines. The study draws on a cross-sectional dataset obtained from 
an online survey with the aim of characterising codeine use amongst NPS users and 
non-NPS users across Europe. Identification of complex substance use patterns 
provide warning of health issues and demand created on treatment services. 
Methods 
The online survey was for adults, at least 18 years of age and residing in a country in 
Europe. Completion of the survey was targeted at those using or had used any type 
of codeine containing medicines in the last 3 months (prescription and ‘over-the-
counter’). The study was granted ethics approval by the Psychiatry, Nursing, and 
Midwifery Research Ethics Subcommittee (PNM RESC), King’s College London. 
REC Reference Number: PNM/14/15-110. 
Recruitment 
Respondents were recruited to attract a broad sample of codeine users, including 
those using for medical and non-medical reasons. A survey link was advertised from 
a website dedicated to health and healthy living, offering information about the use of 
codeine. This site was chosen to recruit individuals with experience of problems and 
harms relating to codeine use. The survey was also advertised from websites, 
Facebook and Twitter accounts belonging to organisations and treatment services 
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offering support and treatment of opioid addiction. The moderator of a drug 
discussion forum was contacted and permission was obtained to post a survey link. 
It has been described how members of this forum share their personal knowledge 
and experiences from using a variety of substances including NPS (Davey, Schifano, 
Corazza, & Deluca, 2012; Soussan & Kjellgren, 2014). Finally, a link to the survey 
were passed on to students and staff at two universities (King’s College London, UK 
and Waterford Institute of Technology, Ireland) via e-mail circulars and Twitter. The 
aim was to recruit young people as well as individuals who use codeine according to 
medical guidance. 
Measurements 
The survey was created in BOS (Bristol Online Survey) and consisted of 49 closed 
and open-ended questions about demographics, codeine consumption and use of 
other substances (See Supplementary File). To identify recent use of codeine, 
respondents were asked to report the frequency of use during the last 3 months. 
Those who had not taken codeine at least once were asked not to complete the 
survey. Dose was measured in milligrams (mg) codeine consumed in a day on the 
last occasion of use. Instructions for how to report the dose in mg were provided. 
Additional questions asked about codeine supply to identify sources of obtaining 
codeine. The responses were: (i) prescribed after a face to face consultation; (ii) 
purchased ‘over-the-counter’ in a pharmacy (no medical prescription required); (iii) 
shop on the Internet; (iv) from family, partner, friends or acquaintances. One 
question asked respondents about purchasing codeine from shops on the Internet 
selling codeine illegally. 
The questionnaire included items from a scale designed to measure reasons for 
substance use (Boys, Marsden & Strang, 2001) to record medical and non-medical 
reasons to take codeine. 
Respondents were asked if they had ever tampered with codeine containing 
medicines. In context of this study, tampering included methods used to enhance 
drug effects (Kimergård et al., 2016a), investigated through a series of questions 
constructed for the study about (i) drinking codeine cough syrups with soft drinks, 
juice, or alcohol; (ii) extracting codeine from tablets containing codeine and non-
opioid analgesics like paracetamol or ibuprofen; (iii) taking codeine rectally; (iv) 
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snorting crushed codeine tablets; (v) injecting dissolved codeine tablets; (vi) 
consuming morphine or heroin manufactured from codeine. 
The degree of psychological dependence on codeine was measured using the 
Severity of Dependence Scale. The scale has previously been used to assess 
codeine dependence (Kimergård et al., 2017; Nielsen, Cameron, & Lee, 2011). The 
scale is easy to administer due to its brevity and consists of five questions scored 
from 0 to 3 for a total score between 0 and 15. The higher the score, the higher 
severity of dependence (Gossop et al., 1995). 
In the last section of the questionnaire, respondents were asked about using NPS 
and illicit controlled drugs. Respondents using NPS were asked to indicate the 
frequency of use over the past 3 months. Respondents were prompted to write in the 
names of the drugs they had taken.  
Data analysis 
Data was downloaded from BOS into SPPS (version 23). Descriptive statistics were 
reported as frequencies and means. Categorical variables were collapsed into binary 
variables for statistical testing. Codeine use was recoded to indicate consumption on 
a daily or non-daily basis. Consumption levels of codeine was captured as a 
continuous variable and re-coded as under or over 240 mg (the recommended 
maximum daily dose, according to the British National Formulary). Logistic 
regression models were used to investigate the association between independent 
variables and the use of NPS. Two groups were created consisting of non-NPS 
users and NPS users. The independent predictor variables were tampering of 
codeine containing medicines, risk behaviours relating to codeine use, main sources 
of obtaining codeine (including prescribed, ‘over-the-counter’, buying online or 
obtained from friends and family), use of illicit controlled drugs and medical and non-
medical reasons to use codeine. 
Results 
Self-reported use of codeine, NPS and illicit controlled drugs were collected from 472 
adult respondents (≥18 years) to an online survey, open between July 2015 and 
March 2016. When classified according to country, 340 respondents residing in a 
country in Europe remained in the final analysis. The mean age was 34.9 years (SD 
= 12.4). The number of female respondents was higher than males at 63.8%. Most 
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respondents resided in the UK (84.1%). A total of 54 respondents came from other 
countries in Europe (15.9%). Just over one-half were in gainful employment (58.2%), 
14.1% received a student allowance, 6.8% depended on others as their main source 
of income and 6.2% received disability allowances. Only 12 respondents reported no 
income (3.5%). 
Codeine use 
In the last 3 months, a total of 273 respondents (80.3%) had used tablets that 
contained codeine in combination with a non-opioid analgesic, such as paracetamol, 
ibuprofen or acetylsalicylic. A lower proportion of 114 respondents (33.5%) had used 
tablets which contained codeine as the only active ingredient. About one out of 
eleven indicated use of codeine containing cough syrups (9.1%). 
Codeine sourcing 
Respondents had obtained codeine from several sources, including purchased ‘over-
the-counter’ in a pharmacy (N = 180; 52.9%); prescribed from a professional after a 
face-to-face consultation (N = 164; 48.2%); obtained from family, partners, friends, 
and acquaintances (for free, purchased, or stolen) (N = 59; 17.4%); and, purchased 
from a shop on the Internet (N = 21; 6.2%). 
A proportion of four respondents (1.2%) had purchased codeine from a shop on the 
Internet which they thought was selling codeine illegally. A further seven 
respondents (2.1%) indicated that they were unsure as to the legality of a shop from 
where they had purchased codeine. When prompted to write in why respondents 
thought the shop was selling codeine illegally, the most common answer was 
because the shop sold high-strength codeine tablets without asking for a medical 
prescription. Purchasing on the hidden web and paying with bitcoins were also 
reported in reply. 
Codeine dependence 
In the full sample of 340 respondents, 59 scored five or above on the Severity of 
Dependence Scale indicating possible dependence upon codeine. Mean SDS score 
was 2.2 (SD = 3.4). 
Polysubstance use amongst respondents with recent codeine use 
One in five (18.5%) had ever used NPS. The highest proportion of them stated that 
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they had not used NPS in the last 3 months (39.7%), 27% indicated that they had 
used NPS once or twice, 17.5% that they had used monthly and 14.3% that they had 
used weekly. Overall, 190 respondents (55.9%) reported life-time use of an illicit 
controlled drug. Of these, a majority indicated use of cannabis. Out of all the 
respondents, 61 (17.9%) reported life-time use of both NPS and illicit controlled 
drugs. Amongst those who exceeded the recommended maximum 24-h dose of 240 
mg codeine on last occasion of use, 17 respondents (5%) had also used NPS and 
reported life-time use of illicit controlled drugs. 
Tampering of codeine containing medicines 
In the logistic regression model, tampering of codeine containing medicines were 
found to significantly predict the use of NPS (Table 1). Compared with non-NPS 
users, NPS users were more likely to consume codeine extracted from tablets 
containing codeine and a non-opioid analgesic (OR = 16.79, 95% CI 8.67−32.51), 
drink codeine cough syrups in a mixture with a soft drink or alcohol (OR = 8.02, 95% 
CI 4.09−15.72) and take codeine rectally to experience effects more intensely (OR = 
4.82, 95% CI 1.63−14.29). No significant differences were found for other tampering 
behaviours between non-NPS users and NPS users. 
Codeine risk behaviours 
Those who had used NPS were less likely to report daily use of codeine (22%) than 
those who had never used NPS (39%) (p < 0.05). Codeine dependence did not 
significantly predict the use of NPS (Table 2). Obtaining codeine through a medical 
prescription was less likely amongst NPS users (22%) in comparison to non-NPS 
users (48%) (p < 0.01). Those reporting use of NPS were more likely to obtain 
codeine from family, partners, friends, and acquaintances (21%) than those not 
reporting use of NPS (6%) (p < 0.01). Buying codeine on the Internet was also 
higher in the NPS user group at 10%, compared to 2% in the non-NPS user group (p 
< 0.01). Compared with those with no use of NPS, NPS users were more likely to 
use illicit controlled drugs (97% compared to 47%, p < 0.01). 
Reasons for codeine use in NPS and non-NPS users 
Use of codeine for non-medical reasons were significant in predicting associations 
with the use of NPS (Table 3). Respondents with use of NPS were more likely to 
have used codeine to get stone or intoxicated (46%) compared to non-NPS users 
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(7%) (p < 0.01). The group using NPS had a higher proportion of respondents using 
codeine to feel elated or euphoric (43%) than the group that had not used NPS 
(10%) (p < 0.01). Users of NPS were more likely than non-NPS users to have used 
codeine to improve the effects of other substances (16% compared to 3%, p < 0.01) 
and to help ease the effects of other substances (14% compared to 4%, p < 0.01). 
Amongst those reporting use of NPS, 60% used codeine as treatment of pain, 
whereas 90% of those not reporting use of NPS used codeine for pain management 
(p < 0.01).  
Discussion 
The study identified a population engaging in complex substance use of a relatively 
young age (mean age = 34.9 years) where specific challenges in terms of 
identification, intervention and treatment exist. The findings of the study add to 
previous studies to underline the potential for misuse and dependence of codeine 
where use of prescribed and ‘over-the-counter’ products for genuine medical 
reasons transitions into problematic use (Cooper, 2013; Kimergård et al., 2017, Van 
Hout et al., 2015). However, our findings also describe codeine use for recreational 
purposes where high doses are consumed to induce opioid euphoria. As part of this 
experimental use, codeine is used in combination with NPS in patterns that also 
involves tampering of codeine containing medicines to experience opioid effects with 
greater intensity. Such ways of combining misused medicines, NPS and illicit 
controlled drugs pose a challenge for public health and highlight the need for policy 
and treatment to respond to a more complex situation than previously faced. 
In the study, approximately one in five codeine users had used NPS and illicit 
controlled drugs. In a qualitative interview study conducted in Australia, Nielsen, 
Cameron, & Pahoki (2013) found that only few users of ‘over-the-counter’ codeine 
reported significant histories of other substance use. However, polysubstance use 
appears far more common in other populations, such as those posting on online drug 
discussion forums. In one study, more than half of those reporting current non-
medical use of prescription opioids on online drug discussion forums were also 
indicating use of other substances, including NPS (Chiauzzi, DasMahapatra, Lobo, & 
Barratt, 2013). 
Respondents who were NPS users were more likely to have obtained codeine from 
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friends, family and acquaintances and from buying on the Internet and less likely to 
obtain codeine from a medical prescription, compared to those who had not used 
NPS. Doses exceeding medicine regulators’ recommendations are typically needed 
to experience a codeine ‘high’, possibly explaining why codeine was obtained from 
multiple and unauthorised sources. Respondents who had used NPS were less likely 
to consume codeine daily than those who had not used NPS. This indicates a 
pattern of less frequent use, but in excessive doses, with the primary aim of inducing 
euphoria and intoxication. 
In this study, NPS users were more likely than non-NPS users to consume codeine 
extracted from combination tablets (codeine/non-opioid analgesics) and to drink 
codeine cough syrups mixed with soft drinks or alcohol. Codeine extraction has been 
described amongst members of drug discussion forums (Cone, 2006; Foley, 
Breindahl, Hindersson, Deluca, & Kimergård, 2016). One study found that extracting 
codeine with the use of simple techniques and household appliances can yield 
different amounts of codeine and non-opioid analgesics in the extracted mixtures 
making it difficult to control the doses (Kimergård, Deluca, Hindersson, & Breindahl, 
2016b). Understanding risk factors associated with medicine tampering may help 
implement harm reduction interventions and deliver treatment to specific populations 
of polysubstance users where the risk of harm is disproportionately great (Kapitány-
Fövény et al., 2015; Kimergård et al., 2016a; Talu et al., 2010). 
Our findings suggest a number of possible explanations for concomitant NPS and 
codeine use: Whilst disruptions to the NPS market may result in delays or 
obstructions in supply, codeine can be obtained relatively easy, including from ‘over-
the-counter’ sales in many European countries (Cooper, 2013; Foley et al., 2015), 
suggesting that codeine is used as a substitute when access to other drugs is 
restricted. Another possible explanation is that codeine is used to ease the after 
effects of other drugs, such as stimulants, as indicated by 14% of NPS users in the 
study. Finally, studies have found that codeine is used non-medically to feel elated 
and intoxicated (Arora et al., 2013; Cooper, 2013; Nielsen et al., 2013), which 
compares favourably to findings of the present study. Still, further research should 
examine in detail the reasons for why NPS and opioid analgesics are used together 
with or in replacement of one another. 
There is a need to make health professionals aware of the emerging trends of 
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combining misused medicines with NPS. Whilst heroin continues to pose a 
significant burden on emergency departments in Europe due to acute drug toxicity, 
data suggest that the mean number of drugs taken per patient has increased in 
many countries (EMCDDA, 2016c). For many new substances, knowledge and data 
can be limited and health professionals may have to respond to symptoms without 
knowing about the drugs taken (Wood, Ceronie, & Dargan, 2016; Guirguis et al., 
2015). Overdoses caused by a combination of opioid analgesics, heroin, alcohol and 
new synthetic opioids can pose a difficult challenge for health professionals because 
of severe toxicity. 
Limitations 
One limitation of online research designs is that certain characteristics of the study 
sample are unknown. This is due to the survey link being posted on the Internet 
amongst (partly) anonymous populations with varying use of codeine and other 
substances. The sample comprised respondents from drug discussion forums, 
where users are known to engage in experimental drug use, but it also included 
individuals recruited from general health forums and from university e-mail circulars 
where use was predominantly within accepted medical guidance. 
Online research will often include respondents from different countries, where the 
availability of codeine and NPS varies. Hence, relating the results to specific 
populations and countries should be done with consideration. Recruiting a greater 
number of respondents could explore national variation in codeine misuse and use of 
NPS. 
Only people with access to the Internet could complete the survey, possibly 
excluding certain populations such as people in prison where high levels of medicine 
misuse and NPS use have been recorded (Kirby, 2016). 
Another limitation is that the use of NPS and illicit controlled drugs may have been 
underreported do to fear of prosecution and stigmatisation, although the levels of 
both misused codeine, illicit controlled drug use and NPS use were high for this type 
of study. Respondents were asked about their use of NPS, which may have resulted 
in under or over-reporting depending on respondents’ understanding and knowledge 
of which drugs are classified as NPS. Respondents were prompted to write in the 
names of drugs they had used, which did provide detailed insight into the abundance 
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of drugs used, but this item had a lower response rate. 
Conclusions 
Few studies have previously investigated recreational codeine use amongst NPS 
and non-NPS users. Amongst NPS users, codeine is less likely to be used daily, but 
more likely to be used for non-medical reasons, than amongst non-NPS users. 
Codeine is obtained from several sources to consume high doses to experience 
opioid euphoria and intoxication. It is a challenge to ensure availability of medicines 
for patients in pain, whilst reducing diversion and harm from recreational use. Many 
people who use NPS obtain information on the Internet from online drug discussion 
forums where users’ experiences of misusing medicines can be found. As such, the 
Internet may provide opportunities to engage with polysubstance users and 
disseminate harm reduction advice when this is available concerning tampering of 
codeine containing medicines. A small group was identified in the study’s findings 
who take multiple drugs in high doses, highlighting need for treatment of acute drug 
toxicity, but also long-term drug addiction. More research should be done to identify 
and characterise high-risk user groups. 
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Tables 
Table 1. Tampering of codeine containing medicines. 
 Non-NPS users 
n = 277 
NPS users 
n = 63 
 




8% 60%** 16.79 (8.67−32.51) 
Drinking codeine 
cough syrups with a 
soft drink, juice or 
alcohol 
8% 40%** 8.02 (4.09−15.72) 
Taken codeine 
rectally to experience 
opioid effects more 
intensely 
3% 11%** 4.82 (1.63−14.29) 
Snorted crushed 
codeine tablets 





0.4% 8%a a 
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Table 2. Codeine use and risk behaviours. 
 Non-NPS users 
n = 277 
NPS users 
n = 63 
 
 % % OR (95% CI) 
Risk behaviours    
Codeine 
dependencea 
17% 17% 1 (0.49−2.08) 
Daily use of codeine 39% 22%* 0.45 (0.24−0.86) 
Primary source of 
codeine 
   
Buying on the 
Internet 
2% 10%** 5.73 (1.69−19.41) 
From family, partner, 
friend, acquaintance 
6% 21%** 3.98 (1.82−8.7) 
‘Over-the-counter’ 
codeine 
43% 44% 1.05 (0.60−1.82) 
Prescribed following 
a consultation with a 
doctor 
48% 22%** 0.31 (0.16−0.58) 
Other substance 
use 
   
Life-time use of illicit 
controlled drugs 
47% 97%** 34.99 (8.39−145.94) 
* P < 0.05; ** P < 0.01; OR, odds ratio; CI, confidence interval. 
a Indicated by a score of ≥5 on the Severity of Dependence Scale. 
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Table 3. Reasons for codeine use in non-NPS users and NPS users. 
 Non-NPS users 
n = 277 
NPS users 
n = 63 
 
 % % OR (95% CI) 
To get stoned or 
intoxicated 
7% 46%** 10.96 (5.6−21.48) 
To improve the 
effects of other 
substances 
3% 16%** 7.28 (2.65−19.98) 
To feel elated or 
euphoric 
10% 43%** 6.41 (3.42−12.04) 
To help relax 20% 56%** 4.93 (2.77−8.78) 
To stop worrying 
about a problem 
9% 33%** 4.83 (2.49−9.35) 
To help ease the 
effects of other 
substances 
4% 14%** 4.45 (1.73−11.47) 
To feel better when 
down or depressed 
14% 43%** 4.44 (2.44−8.11) 
To ease withdrawal 
symptoms of 
opioids 
4% 13%** 3.88 (1.47−10.29) 
To help sleep 21% 41%** 2.65 (1.49−4.74) 
To treat pain 90% 60%** 0.16 (0.09−0.31) 
** P < 0.01; OR, odds ratio; CI, confidence interval. 
 
